通过排除父源突变对单基因病进行无创产前诊断:3年临床经验
法国多中心描述性研究,评估游离胎儿DNA分析在单基因病中排除父源变异体的标准化方案,对25%或50%父源遗传风险的妊娠及新发变异相关妊娠进行检测,平均报告时间6天,198例转诊中除2例外均获结果。
要点
- 该服务已成功作为常规实验室实践实施。
- 平均新检测设计验证时间14天,平均结果报告时间6天。
- 198例转诊中,除位于复杂基因组区域的1个致病变异外均可靶向,除2例外均获结果。
核心结论
- 该服务已成功作为常规实验室实践实施,并被法国临床医生和患者广泛采用,用于多种疾病中父源变异体的排除。
研究设计与样本
- 描述性研究,法国多中心,转诊指征包括25%或50%父源遗传单基因病风险的妊娠,以及因新发变异导致的单基因病风险增加的妊娠(来自强烈提示的超声发现或可能父母生殖腺嵌合)。
- 无创产前诊断使用定制试剂盒进行微滴式数字PCR,评估可行性、诊断性能和周转时间。
主要发现
- 平均新检测设计验证时间为14天,平均结果报告时间为6天。
- 所有转诊的致病变异均可靶向,除1个位于复杂基因组区域外。
- 198例转诊中除2例外均获得结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cell-free fetal DNA (cffDNA) analysis is performed routinely for aneuploidy screening, RhD genotyping or sex determination. Although applications to single gene disorders (SGD) are being rapidly developed worldwide, only a few laboratories offer cffDNA testing routinely as a diagnosis service for this indication. In a previous report, we described a standardised protocol for non-invasive exclusion of paternal variant in SGD. Three years later, we now report our clinical experience with the protocol. DESIGN: Descriptive study. SETTING: Multi-centre French. POPULATION: Indications for referral included pregnancies at risk of 25% or 50% of paternally inherited SGD, and pregnancies associated with an increased risk of SGD due to a de novo variant, either from strongly suggestive ultrasound findings or from a possible parental germinal mosaicism in the context of a previously affected child. METHODS: Non-invasive prenatal diagnosis was performed using custom assays for droplet digital PCR. Feasibility, diagnostic performance and turn-around time were evaluated. RESULTS: Mean time for a new assay design and validation was evaluated at 14 days, and mean result reporting time was 6 days. All referred pathogenic variants could be targeted except one located in a complex genomic region. A result was obtained for every 198 referrals except two. CONCLUSION: This service was successfully implemented as a routine laboratory practice. It has been widely adopted by French clinicians and patients for paternal variant exclusion in various disorders. TWEETABLE ABSTRACT: A robust approach to non-invasive prenatal exclusion of paternal pathogenic variant in a diagnosis setting.
引用
- Pacault M, Verebi C, Lopez M, et al. Non-invasive prenatal diagnosis of single gene disorders by paternal mutation exclusion: 3 years of clinical experience. BJOG. 2022. PMID: 35486001. doi:10.1111/1471-0528.17201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。